INVA Innoviva, Inc.

Nasdaq Pharmaceutical Preparations DE CIK: 0001080014
AI RATING
BUY
65% Confidence

Investment Thesis

Innoviva demonstrates exceptional fundamental strength with 1850% revenue growth and fortress-level financials (77.4% gross margin, $603.1M cash, 0.19x debt/equity). However, net income appears heavily influenced by non-recurring items (net margin exceeding 100% while operating margin is 38.9%), creating uncertainty around sustainable profitability that warrants closer investigation.

Strengths

  • + Exceptional revenue growth of 1850.7% YoY demonstrates powerful market demand and scaling
  • + Fortress balance sheet with $603.1M cash, minimal leverage (0.19x debt/equity), and exceptional liquidity (21.13x current ratio)
  • + Outstanding operational efficiency with 77.4% gross margin and 38.9% operating margin; strong free cash flow generation at 35.5% FCF margin

Risks

  • ! Net income flat YoY despite 1850% revenue growth indicates substantial non-recurring items or accounting adjustments distorting earnings quality
  • ! Net margin of 190.4% exceeding gross revenue is mathematically inconsistent with operating metrics, suggesting major one-time gains masking sustainable profitability
  • ! Significant divergence between reported net income ($186.6M) and operating cash flow ($35.3M) indicates reliance on non-cash gains rather than operational cash generation

Key Metrics to Watch

Financial Metrics

Revenue
98.0M
Net Income
186.6M
EPS (Diluted)
$2.22
Free Cash Flow
34.8M
Total Assets
1.8B
Cash
603.1M

Profitability Ratios

Gross Margin 77.4%
Operating Margin 38.9%
Net Margin 190.4%
ROE 13.9%
ROA 10.2%
FCF Margin 35.5%

Balance Sheet & Liquidity

Current Ratio
21.13x
Quick Ratio
20.07x
Debt/Equity
0.19x
Debt/Assets
0.0%
Interest Coverage
7.02x
Long-term Debt
258.1M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-08T10:43:30.033123 | Data as of: 2026-03-31 | Powered by Claude AI